BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says ANTI-PD-L1 Tagitanlimab Approved For Marketing By NMPA

Like
Comment
Favorite

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says ANTI-PD-L1 Tagitanlimab Approved For Marketing By NMPA

Reuters01-20

Jan 20 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd :

* ANTI-PD-L1 TAGITANLIMAB APPROVED FOR MARKETING BY NMPA

Further company coverage:

((Reuters.Briefs@thomsonreuters.com;;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

01:49
Advance ZincTek - Plan to Increase Stock Levels and Ship to USA Over Next 6 Months to Avoid Additional Costs to USA Customers
01:47
Japan's Nikkei Share Average Pares Gains, Last up 0.34%
01:45
S&P Global Ratings- Tightening Regulations in Indian Microfinance to Rein in Growth Plans for Sector Lenders
01:31
China's Yuan Opens Trade at 7.2600 per Dollar VS Last Close at 7.2593
01:27
Pakistan Ambassador to China, on China's Proposed Joint Security System: There Is a High Degree of Trust Between US, We Will Continue to Take Measures Which Are Effective

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2504284876?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-01-20 23:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2504284876","market":"sh","top_or_hot":-1,"title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says ANTI-PD-L1 Tagitanlimab Approved For Marketing By NMPA","media":"Reuters","content":"<html><body><p>Jan 20 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd   :</p><p>   * ANTI-PD-L1 TAGITANLIMAB APPROVED FOR MARKETING BY NMPA</p><p>Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says ANTI-PD-L1 Tagitanlimab Approved For Marketing By NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says ANTI-PD-L1 Tagitanlimab Approved For Marketing By NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-20 23:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Jan 20 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd   :</p><p>   * ANTI-PD-L1 TAGITANLIMAB APPROVED FOR MARKETING BY NMPA</p><p>Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0196878994.USD","symbol_name":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2504284876","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2504284876","pubTimestamp":1737386939,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Jan 20 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd   :   * ANTI-PD-L1 TAGITANLIMAB APPROVED FOR MARKETING BY NMPAFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;;))","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","06990":"科伦博泰生物-B","BK1161":"生物科技"},"translate_title":"简报-四川科伦生物制药称抗PD-L1塔吉坦利单抗获NMPA批准上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":0.9},"content_text":"Jan 20 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd   :   * ANTI-PD-L1 TAGITANLIMAB APPROVED FOR MARKETING BY NMPAFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}